Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist

Overview of attention for article published in PharmacoEconomics, April 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source
twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 73 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 X post from an account with 721 followers.

#HealthEconJA Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist https://t.co/wRoXtITLwT

17 Apr 2018

Reply Repost Favourite